S-adenozylmetionín – SAMe

Literatúra

  1. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia.
  2. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study.
  3. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer’s disease: a 1-year, open-label pilot study with an 16-month caregiver extension.
  4. S-Adenosylmethionine (Ademetionine) in Psychiatric Disorders: Historical Perspective and Current Status.
  5. Bottiglieri T, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. (2000)
  6. Loehrer FM, et al. Influence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humans. J Pharmacol Exp Ther. (1997)
  7. Thompson MA, et al. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial. J Altern Complement Med. (2009)
  8. Struys EA, et al. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometry. Clin Chem. (2000)
  9. Bell KM, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand Suppl. (1994)
  10. Shippy RA, et al. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry. (2004)
  11. S-Adenosylmethionine Levels in the Diagnosis of Pneumocystis carinii Pneumonia in Patients with HIV Infection.
  12. Bottiglieri T, et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. (1990)
  13. Poirier LA, et al. Blood S-adenosylmethionine concentrations and lymphocyte methylenetetrahydrofolate reductase activity in diabetes mellitus and diabetic nephropathy. Metabolism. (2001)
  14. Maj M, Zizolfi S, Del Vecchio M. Blood levels of S-adenosylmethionine in unmedicated schizophrenic and depressive patients. Neuropsychobiology. (1981)
  15. Andreoli VM, Maffei F, Tonon GC. S-adenosyl-L-methionine (SAMe) blood levels in schizophrenia and depression. Monogr Gesamtgeb Psychiatr Psychiatry Ser. (1978)
  16. Strous RD, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol. (2009)
  17. Stabler SP, et al. Elevated serum S-adenosylhomocysteine in cobalamin-deficient elderly and response to treatment. Am J Clin Nutr. (2006)
  18. Poirier LA, et al. Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with diet. Cancer Epidemiol Biomarkers Prev. (2001)
  19. Stramentinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med. (1987)
  20. Silveri MM, et al. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol Psychiatry. (2003)
  21. Dunne JB, et al. Evidence that S-adenosyl-L-methionine diastereoisomers may reduce ischaemia-reperfusion injury by interacting with purinoceptors in isolated rat liver. Br J Pharmacol. (1998)
  22. Hoffman JL. Chromatographic analysis of the chiral and covalent instability of S-adenosyl-L-methionine. Biochemistry. (1986)
  23. Lee S, et al. Steric Course of the Methyl Transfer from AdoMet to S-Farnesyl-3-thiopropionate by G-Protein Methyltransferase. J Org Chem. (1998)
  24. Kealey JT, et al. Stereochemistry of methyl transfer catalyzed by tRNA (m5U54)-methyltransferase–evidence for a single displacement mechanism. Nucleic Acids Res. (1991)
  25. Woodard RW, et al. Stereochemical course of the transmethylation catalyzed by catechol O-methyltransferase. J Biol Chem. (1980)
  26. Borchardt RT, Wu YS. Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 5. Role of the asymmetric sulfonium pole in the enzymatic binding of S-adenosyl-L-methionine. J Med Chem. (1976)
  27. Najm WI, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. {ISRCTN36233495}. BMC Musculoskelet Disord. (2004)
  28. McMillan JM, Walle UK, Walle T. S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol. (2005)
  29. Yang J, et al. Pharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers. Clin Ther. (2009)
  30. Giulidori P, et al. Pharmacokinetics of S-adenosyl-L-methionine in healthy volunteers. Eur J Clin Pharmacol. (1984)
  31. Agrimi G, et al. Identification of the human mitochondrial S-adenosylmethionine transporter: bacterial expression, reconstitution, functional characterization and tissue distribution. Biochem J. (2004)
  32. Dridi L, Ahmed Ouameur A, Ouellette M. High affinity S-Adenosylmethionine plasma membrane transporter of Leishmania is a member of the folate biopterin transporter (FBT) family. J Biol Chem. (2010)
  33. Horne DW, Holloway RS, Wagner C. Transport of S-adenosylmethionine in isolated rat liver mitochondria. Arch Biochem Biophys. (1997)
  34. Williams AC, Ramsden DB. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. Med Hypotheses. (2005)
  35. Pavia J, et al. Effect of S-adenosyl methionine on muscarinic receptors in young rats. Life Sci. (1997)
  36. Muccioli G, et al. Effect of S-adenosyl-L-methionine on brain muscarinic receptors of aged rats. Eur J Pharmacol. (1992)
  37. Chan A, et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: critical role of S-adenosyl methionine. J Nutr Health Aging. (2008)
  38. Shea TB, Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer’s disease. J Alzheimers Dis. (2008)
  39. Fava M, et al. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. (1997)
  40. Alpert JE, et al. Nutrition and depression: focus on folate. Nutrition. (2000)
  41. Bottiglieri T, et al. Transmethylation in depression. Ala J Med Sci. (1988)
  42. Matthysse S, Baldessarini RJ. S-adenosylmethionine and catechol-O-methyl-transferase in schizophrenia. Am J Psychiatry. (1972)
  43. Tolbert LC. MAT kinetics in affective disorders and schizophrenia. An account. Ala J Med Sci. (1988)
  44. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. (1994)
  45. Saletu-Zyhlarz GM, et al. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with antidepressant properties, by pharmaco-EEG mapping. Int J Neuropsychopharmacol. (2002)
  46. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence.
  47. Fava M, et al. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res. (1995)
  48. Berlanga C, et al. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. (1992)
  49. Papakostas GI, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. (2010)
  50. Fleisch SB, Travis MJ, Ryan ND. Discrepancy in response and remission rates for SAMe-treated patients in a double-blind, randomized clinical trial. Am J Psychiatry. (2010)
  51. Alpert JE, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. (2004)
  52. Sarris J1, et al. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. (2014)
  53. Strous RD, et al. Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am J Med Genet B Neuropsychiatr Genet. (2003)
  54. Strous RD, et al. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res. (1997)
  55. Di Rocco A, et al. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord. (2000)
  56. Levkovitz Y, et al. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. (2012)
  57. Arnold O, et al. Double-blind, placebo-controlled pharmacodynamic studies with a nutraceutical and a pharmaceutical dose of ademetionine (SAMe) in elderly subjects, utilizing EEG mapping and psychometry. Eur Neuropsychopharmacol. (2005)
  58. Spijkerman AM, et al. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study. Arterioscler Thromb Vasc Biol. (2005)
  59. Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease.
  60. Mischoulon D, et al. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. (2012)
  61. Gören JL, et al. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy. (2004)
  62. Tavoni A, et al. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. Am J Med. (1987)
  63. Volkmann H, et al. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. Scand J Rheumatol. (1997)
  64. Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol. (1991)
  65. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. (2007)
  66. Kalhan SC, et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin Sci (Lond). (2011)
  67. Loguercio C, et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol. (1994)
  68. Chawla RK, et al. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology. (1984)
  69. Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med. (2009)
  70. Mato JM, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. (1999)
  71. Santini D, et al. S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. Anticancer Res. (2003)
  72. Binder T, et al. Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. J Perinat Med. (2006)
  73. Roncaglia N, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG. (2004)
  74. Nicastri PL, et al. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy. Br J Obstet Gynaecol. (1998)
  75. Floreani A, et al. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur J Obstet Gynecol Reprod Biol. (1996)
  76. Ribalta J, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology. (1991)
  77. Duong FH, et al. S-Adenosylmethionine and betaine correct hepatitis C virus induced inhibition of interferon signaling in vitro. Hepatology. (2006)
  78. Duong FH, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology. (2004)
  79. Duong FH, et al. Upregulation of protein phosphatase 2Ac by hepatitis C virus modulates NS3 helicase activity through inhibition of protein arginine methyltransferase 1. J Virol. (2005)
  80. Filipowicz M, et al. S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. PLoS One. (2010)
  81. Feld JJ, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. (2011)
  82. Medici V, et al. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial. Alcohol Clin Exp Res. (2011)
  83. Caruso I, Pietrogrande V. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease. Am J Med. (1987)
  84. Witte S, Lasek R, Victor N. Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis. Orthopade. (2002)
  85. Soeken KL, et al. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. J Fam Pract. (2002)
  86. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med. (1987)
  87. Kim J, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. (2009)
  88. Papadopoulos V, et al. Effects of the transmethylation inhibitor S-adenosyl-homocysteine and of the methyl donor S-adenosyl-methionine on rat Leydig cell function in vitro. J Steroid Biochem. (1987)
  89. Manteuffel-Cymborowska M, Chmurzynska W, Grzelakowska-Sztabert B. Tissue-specific effects of testosterone on S-adenosylmethionine formation and utilization in the mouse. Biochim Biophys Acta. (1992)
  90. Heljasvaara R, et al. Transgenic mice overexpressing ornithine and S-adenosylmethionine decarboxylases maintain a physiological polyamine homoeostasis in their tissues. Biochem J. (1997)
  91. Crozat A, et al. Comparison of androgen regulation of ornithine decarboxylase and S-adenosylmethionine decarboxylase gene expression in rodent kidney and accessory sex organs. Endocrinology. (1992)
  92. Fjösne HE, Strand H, Sunde A. Dose-dependent induction of ornithine decarboxylase and S-adenosyl-methionine decarboxylase activity by testosterone in the accessory sex organs of male rats. Prostate. (1992)
  93. de las Heras MA, Calandra RS. S-adenosyl-L-methionine decarboxylase activity in the rat epididymis: ontogeny and androgenic control. J Androl. (1991)
  94. Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease. Clin Neuropharmacol. (2005)
  95. Kagan BL, et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. (1990)